Christopher Gibson
Chief Executive Officer at Recursion Pharmaceuticals Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Recursion Pharmaceuticals Inc., 3 years.
Recursion Pharmaceuticals Inc.
Director · Chief Executive Officer
Chief executive roles
Recursion Pharmaceuticals Inc.
· Chief Executive Officer
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 5, 2024 | Recursion Pharmaceuticals Inc. | Derivative conversion | +20,000 | — | — |
| Sep 5, 2024 | Recursion Pharmaceuticals Inc. | Open-market sale | −20,000 | $6.14 | $122,800 |
| Sep 4, 2024 | Recursion Pharmaceuticals Inc. | Derivative conversion | +20,000 | — | — |
| Sep 4, 2024 | Recursion Pharmaceuticals Inc. | Open-market sale | −20,000 | $6.04 | $120,800 |
| Aug 30, 2024 | Recursion Pharmaceuticals Inc. | Option exercise | +5,000 | $2.48 | $12,400 |
| Aug 29, 2024 | Recursion Pharmaceuticals Inc. | Option exercise | +5,000 | $2.48 | $12,400 |
| Aug 28, 2024 | Recursion Pharmaceuticals Inc. | Option exercise | +5,000 | $2.48 | $12,400 |
| Aug 27, 2024 | Recursion Pharmaceuticals Inc. | Option exercise | +5,000 | $2.48 | $12,400 |
| Aug 26, 2024 | Recursion Pharmaceuticals Inc. | Option exercise | +5,000 | $2.48 | $12,400 |
| Aug 23, 2024 | Recursion Pharmaceuticals Inc. | Option exercise | +5,000 | $2.48 | $12,400 |
| Aug 15, 2024 | Recursion Pharmaceuticals Inc. | Shares withheld for tax | −26,082 | $6.69 | $174,489 |
| Aug 8, 2024 | Recursion Pharmaceuticals Inc. | Derivative conversion | +20,000 | — | — |
| Aug 8, 2024 | Recursion Pharmaceuticals Inc. | Open-market sale | −20,000 | $6.50 | $130,000 |
| Aug 7, 2024 | Recursion Pharmaceuticals Inc. | Derivative conversion | +30,000 | — | — |
| Aug 7, 2024 | Recursion Pharmaceuticals Inc. | Open-market sale | −30,000 | $7.10 | $213,000 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.